CN104395343A - 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案 - Google Patents

抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案 Download PDF

Info

Publication number
CN104395343A
CN104395343A CN201380035806.8A CN201380035806A CN104395343A CN 104395343 A CN104395343 A CN 104395343A CN 201380035806 A CN201380035806 A CN 201380035806A CN 104395343 A CN104395343 A CN 104395343A
Authority
CN
China
Prior art keywords
nogo
antibody
colocalization
days
dose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380035806.8A
Other languages
English (en)
Chinese (zh)
Inventor
J.布尔曼
D.克鲁尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN104395343A publication Critical patent/CN104395343A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201380035806.8A 2012-07-05 2013-07-03 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案 Pending CN104395343A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261668134P 2012-07-05 2012-07-05
US61/668134 2012-07-05
PCT/EP2013/064063 WO2014006105A1 (en) 2012-07-05 2013-07-03 Optimum dose regime of an anti-nogo-a antibody in the treatment of amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
CN104395343A true CN104395343A (zh) 2015-03-04

Family

ID=48741180

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380035806.8A Pending CN104395343A (zh) 2012-07-05 2013-07-03 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案

Country Status (10)

Country Link
EP (1) EP2870177A1 (https=)
JP (1) JP2015521992A (https=)
KR (1) KR20150036398A (https=)
CN (1) CN104395343A (https=)
AU (1) AU2013285493A1 (https=)
BR (1) BR112014032987A2 (https=)
CA (1) CA2876284A1 (https=)
IN (1) IN2014KN02952A (https=)
RU (1) RU2014150265A (https=)
WO (1) WO2014006105A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102279751B1 (ko) * 2019-06-28 2021-07-21 경북대학교 산학협력단 근원성 인자 또는 nogo-a 측정 제제를 포함하는 근육병 진단용 조성물과 이를 이용한 근육병 진단 방법
KR102409771B1 (ko) * 2020-06-17 2022-06-16 경북대학교 산학협력단 Nogo-A 및 필라민-C의 상호 결합을 이용한 근육질환의 치료제 스크리닝 방법
WO2026041734A1 (en) * 2024-08-22 2026-02-26 Novago Therapeutics Ag Methods for treating neurological disorders using anti-nogo-a antibodies

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57106673A (en) 1980-12-24 1982-07-02 Chugai Pharmaceut Co Ltd Dibenzo(b,f)(1,4)oxazepin derivative
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
GB0228832D0 (en) 2002-12-10 2003-01-15 Novartis Ag Organic compound
DE10336350B4 (de) 2003-08-08 2007-10-31 Westfalia Separator Ag Vollmantel-Schneckenzentrifuge, mit Schälscheibe
GB0321997D0 (en) 2003-09-19 2003-10-22 Novartis Ag Organic compound
CA2549956C (en) 2003-12-22 2016-04-12 Glaxo Group Limited Immunoglobulins
GB0525662D0 (en) 2005-12-16 2006-01-25 Glaxo Group Ltd Immunoglobulins
HRP20130699T1 (hr) 2007-11-02 2013-11-22 Novartis Ag Poboljšane molekule koje se vežu na nogo-a i njihova farmaceutska uporaba
JP2011527317A (ja) 2008-07-11 2011-10-27 グラクソ グループ リミテッド Ｎｏｇｏ−ａアンタゴニストによる筋萎縮性側索硬化症の治療

Also Published As

Publication number Publication date
AU2013285493A1 (en) 2015-01-22
RU2014150265A (ru) 2016-08-27
WO2014006105A1 (en) 2014-01-09
KR20150036398A (ko) 2015-04-07
JP2015521992A (ja) 2015-08-03
EP2870177A1 (en) 2015-05-13
IN2014KN02952A (https=) 2015-05-08
CA2876284A1 (en) 2014-01-09
BR112014032987A2 (pt) 2017-06-27

Similar Documents

Publication Publication Date Title
JP5513380B2 (ja) 肝細胞増殖因子に対する特異的結合剤の組成物
US7785587B2 (en) Therapeutic methods for muscular or neuromuscular disorders
KR101820582B1 (ko) 항체 제제 및 이의 용도
JP2020518599A (ja) プログラム死受容体１（ｐｄ−１）抗体の安定製剤およびその使用方法
TW201400132A (zh) 改善血腦屏障運送之安全性之方法
KR20110097772A (ko) 생리적 조건하에 거대분자의 응집을 감소시키는 방법 및 제제
EA028574B1 (ru) Способ лечения b-клеточных злокачественных новообразований, экспрессирующих cd19
KR20110086705A (ko) 생리학적 조건 하에 거대분자의 응집을 감소시키는 방법 및 제제
WO2018067819A1 (en) Compositions and methods for treatment of cancers
US20250011416A1 (en) Methods for the treatment of cardiovascular disease
TWI807338B (zh) 結合ＴＧＦ-α及表皮調節素（ＥＰＩＲＥＧＵＬＩＮ）之抗體於治療疼痛之用途
TWI802942B (zh) Pd-l1/lag-3雙特異性抗體製劑及其製備方法和用途
CN104395343A (zh) 抗Nogo-A抗体在肌萎缩侧索硬化治疗中的最佳剂量方案
US20170233467A1 (en) Antibodies Directed to Angiopoietin-1 and Angiopoietin-2 for Ocular Therapies
KR20230020449A (ko) 레빌리맙의 수성 약학적 조성물
US20240382411A1 (en) Composition comprising pd-l1 antigen-binding fragment and use thereof
WO2025072725A9 (en) Methods for the treatment of cardiovascular disease
WO2024104409A1 (zh) 一种含抗rankl-ngf双特异性抗体的药物组合物
WO2026072994A1 (en) Methods for the treatment of cardiovascular disease
WO2024112561A1 (en) Methods for the treatment of myasthenia gravis
WO2025006774A1 (en) Method of treating osteoarthritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20150304

WD01 Invention patent application deemed withdrawn after publication